AIM
AIM ImmunoTech Inc.
+0.00 (+1.00%)0.21USD1.4M成交股數6.5M市值–本益比(近四季)68.0股價營收比+4.0%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 26K+4% | 22K+38% | 21K-40% | 26K-48% | 25K-38% | 16K-75% | 35K-24% | 50K+19% | 40K | 65K | 46K | 42K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 589K | 482K | 1.1M | 607K | 1.2M | 1.1M | 1.4M | 1.1M | 2.0M | 3.2M | 2.7M | 3.0M |
| 銷售管理費用 | 2.9M | 1.8M | 1.9M | 1.8M | 1.5M | 2.5M | 3.1M | 2.6M | 3.8M | 10.9M | 5.4M | 2.6M |
| 營業利益 | −3.5M+33% | −2.2M-38% | −3.0M-34% | −2.4M-34% | −2.6M-54% | −3.6M-74% | −4.5M-45% | −3.7M-32% | −5.7M | −14.0M | −8.2M | −5.5M |
| 營業利益率 | -13,511.5% | -10,118.2% | -14,057.1% | -9,411.5% | -10,584.0% | -22,618.8% | -12,825.7% | -7,388.0% | -14,335.0% | -21,543.1% | -17,732.6% | -13,002.4% |
| 稅後淨利 | −3.8M+36% | −3.0M-18% | −4.2M+13% | −3.3M+79% | −2.8M-52% | −3.7M-71% | −3.7M-53% | −1.8M-63% | −5.8M | −12.6M | −7.8M | −4.9M |
| 淨利率 | -14,569.2% | -13,740.9% | -19,881.0% | -12,630.8% | -11,176.0% | -23,156.3% | -10,571.4% | -3,672.0% | -14,542.5% | -19,347.7% | -16,991.3% | -11,688.1% |
| 稀釋 EPS | -0.43-88% | -0.69+1280% | -6.46+8% | 1.57-152% | -3.68+2967% | -0.05-81% | -6.00+3650% | -3.00+2900% | -0.12 | -0.26 | -0.16 | -0.10 |
| 稀釋股數 | 17.1M | 4.4M | 1.6M | 2.1M | 759K | 703K | 577K | 528K | 49.5M | 48.6M | 48.6M | 48.4M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 9.9M | 5.8M | 3.0M | 2.3M | 476K | 898K | 915K | 3.6M | 3.3M | 5.4M | 15.3M | 21.0M |
| 應收帳款 | – | – | 7K | – | – | – | – | – | – | 1.2M | 48K | 33K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 12.7M | 8.6M | 5.8M | 5.5M | 4.1M | 6.2M | 13.6M | 15.7M | 16.2M | 19.4M | 27.9M | 33.6M |
| 有息負債 | 3.6M | 210K | 927K | – | 2.7M | 2.4M | 139K | 283K | 950K | – | – | – |
| 總負債 | 5.0M | 6.5M | 15.6M | 11.6M | 10.7M | 10.1M | 10.7M | 9.6M | 11.4M | 9.1M | – | – |
| 股東權益 | 7.7M | 2.1M | −9.8M | −6.1M | −6.5M | −3.9M | 2.9M | 6.1M | 4.8M | 10.2M | 22.6M | 30.1M |
| 負債比 | 39.2% | 75.2% | 269.2% | 210.6% | 258.5% | 161.7% | 78.6% | 61.2% | 70.2% | 47.2% | – | – |
| 淨現金(現金 − 有息負債) | 6.3M | 5.6M | 2.1M | – | −2.2M | −1.5M | 776K | 3.3M | 2.3M | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −2.7M+15% | – | – | – | −2.4M | – | – | −4.8M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2022 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2022 年度 · 141K
| Clinical Treatment Programs US | 141K | 100.0% | +4.4% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 88K | -48.2% | −14.0M | -15,861.4% | -8.62 | – |
| FY2024 | 170K | -15.8% | −17.3M | -10,188.2% | -30.92 | −14.9M |
| FY2023 | 202K | +43.3% | −29.0M | -14,337.6% | -0.60 | – |
| FY2022 | 141K | +4.4% | −19.4M | -13,790.8% | -0.40 | −16.2M |
| FY2021 | 135K | -17.2% | −19.1M | -14,168.1% | -0.40 | −14.0M |
| FY2020 | 163K | +16.4% | −14.4M | -8,834.4% | -0.45 | −10.4M |
| FY2019 | 140K | -61.9% | −9.4M | -6,717.1% | -2.58 | −9.1M |
| FY2018 | 367K | – | −9.8M | -2,677.7% | -9.77 | −10.7M |